ConfidentialAln-At3 Global License Terms • August 6th, 2019 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
THESE AMENDED AND RESTATED ALN-AT3 GLOBAL LICENSE TERMS (this “Agreement”) are entered into as of April 8, 2019 (the “A&R Execution Date”), by and between Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“Alnylam”), and Genzyme Corporation, a corporation organized and existing under the laws of the Commonwealth of Massachusetts (“Genzyme”). Except where otherwise specifically provided herein, the amendments to the rights and obligations in the Original Agreement that are set forth herein shall only become binding upon the Effective Date (as defined below).
